Under the deal, Boston Scientific will acquire Devoro Medical’s Wolf thrombectomy platform, a device that captures blood clots using fingerlike prongs. It was designed to remove blood clots without damaging blood vessels and while minimizing blood loss.
Boston Scientific has been an investor in Devoro Medical since 2019 and currently holds an equity stake of about 16 percent.
The company will pay $269 million for the remaining 84 percent stake not yet owned and up to an additional $67 million dependent on certain clinical and regulatory milestones.
The deal is expected to close in the fourth quarter of 2021.
Read Boston Scientific’s full news release here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
